Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) and Applied Therapeutics (NASDAQ:APLT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.
Profitability
This table compares Akebia Therapeutics and Applied Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akebia Therapeutics | -22.60% | -156.59% | -11.53% |
| Applied Therapeutics | N/A | -340.84% | -175.00% |
Earnings and Valuation
This table compares Akebia Therapeutics and Applied Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Akebia Therapeutics | $197.20 million | 0.63 | -$5.34 million | ($0.16) | -2.80 |
| Applied Therapeutics | $1.00 million | 15.86 | -$105.62 million | ($0.10) | -1.03 |
Akebia Therapeutics has higher revenue and earnings than Applied Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Akebia Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Akebia Therapeutics and Applied Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akebia Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Applied Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
Akebia Therapeutics presently has a consensus target price of $3.50, indicating a potential upside of 680.21%. Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics’ higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Akebia Therapeutics.
About Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for people affected by kidney disease. Founded in 2007 and based in Cambridge, Massachusetts, the company’s work has centered on anemia and other complications associated with chronic kidney disease. Its products include Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and Auryxia (ferric citrate).
About Applied Therapeutics
Applied Therapeutics is a biotechnology company focused on developing small-molecule medicines for rare metabolic and other serious diseases. Founded in 2016, the company is based in New York and was founded by Shoshana Shendelman, who has served as its chief executive officer. The company’s pipeline has centered on govorestat, an investigational inhibitor of the enzyme aldose reductase. Applied Therapeutics has studied the drug in conditions including classic galactosemia, SORD deficiency and PMM2-CDG, disorders that can affect multiple body systems and have limited treatment options.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
